NasdaqGS - Nasdaq Real Time Price • USD
REGENXBIO Inc. (RGNX)
As of 1:54 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 11 | 11 |
| Avg. Estimate | -1.26 | -1.22 | -4.53 | -2.19 |
| Low Estimate | -1.5 | -1.4 | -5.66 | -5.15 |
| High Estimate | -1.11 | -1.06 | -1.41 | 1.45 |
| Year Ago EPS | -1.53 | -1.66 | -6.02 | -4.53 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 12 | 12 |
| Avg. Estimate | 23.52M | 25.23M | 133.61M | 234.7M |
| Low Estimate | 16.69M | 20M | 80M | 80M |
| High Estimate | 34.7M | 34.7M | 284.76M | 414M |
| Year Ago Sales | 19.14M | -- | 90.24M | 133.61M |
| Sales Growth (year/est) | 22.90% | -- | 48.10% | 75.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.54 | -1.38 | -1.52 | -1.27 |
| EPS Actual | -1.53 | -1.66 | -1.41 | -1.43 |
| Difference | 0.01 | -0.28 | 0.11 | -0.16 |
| Surprise % | 0.60% | -20.30% | 7.20% | -12.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.26 | -1.22 | -4.53 | -2.19 |
| 7 Days Ago | -1.26 | -1.22 | -4.53 | -2.19 |
| 30 Days Ago | -1.26 | -1.22 | -4.53 | -2.19 |
| 60 Days Ago | -1.16 | -1.13 | -3.6 | -2.47 |
| 90 Days Ago | -1.14 | -1.09 | -3.4 | -2.22 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RGNX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 17.60% | -- | -- | 0.30% |
| Next Qtr. | 26.50% | -- | -- | 9.80% |
| Current Year | 24.80% | -- | -- | 4.50% |
| Next Year | 51.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 13.60% | -- | -- | 11.06% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Stifel: Buy to Buy | 4/12/2024 |
| Initiated | HC Wainwright & Co.: Buy | 3/11/2024 |
| Upgrade | RBC Capital: Sector Perform to Outperform | 3/8/2024 |
| Maintains | Chardan Capital: Buy to Buy | 3/7/2024 |
| Maintains | Barclays: Overweight to Overweight | 3/7/2024 |
| Upgrade | Leerink Partners: Market Perform to Outperform | 3/6/2024 |
Related Tickers
QURE uniQure N.V.
4.5850
-3.47%
RARE Ultragenyx Pharmaceutical Inc.
44.90
-0.47%
VYGR Voyager Therapeutics, Inc.
7.59
-0.78%
FDMT 4D Molecular Therapeutics, Inc.
24.83
+0.08%
ETNB 89bio, Inc.
8.58
-3.81%
PMVP PMV Pharmaceuticals, Inc.
1.7400
-3.60%
MGTX MeiraGTx Holdings plc
4.8600
-1.42%
ARGX argenx SE
376.39
+0.35%
ADVM Adverum Biotechnologies, Inc.
10.63
-3.41%
MGNX MacroGenics, Inc.
15.87
-2.22%